2014 FEB 10 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Researchers detail new data in Immune System Diseases and Conditions. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "ObjectivesPegylated-interferon/ribavirin dual therapy for hepatitis C virus (HCV) infection has a lower sustained virological response (SVR) rate in HIV/HCV-coinfected patients than in HCV monoinfected patients, but little is known about the relative effectiveness of teleprevir-based triple therapy in the two groups. MethodsData on 33 coinfected and 116 monoinfected patients were analysed on an intention-to-treat basis."
Our news editors obtained a quote from the research from Johns Hopkins University, "SVR12 was defined as undetectable HCV RNA at week 12 post-end-of-treatment, severe anaemia as haemoglobin 89g/L or a drop of 45g/L, and advanced fibrosis/cirrhosis as Fib-4 3.25. All coinfected patients had well controlled HIV infection. ResultsThe groups were similar in age, gender, percentage with Fib-4 3.25 and HCV viral load, but differed in previous treatment response, with more coinfected patients being nonresponders or treatment-intolerant (75.8% vs. 50.0% for monoinfected patients; P<0.01). During treatment, the percentages of patients with undetectable HCV RNA were similar, but, surprisingly, this percentage tended to be higher in coinfected patients. SVR12 rates were 60.6% in coinfected patients vs. 42.2% in monoinfected patients (P=0.06). In multivariable analysis, SVR12 was associated with HIV infection [odds ratio (OR) 3.55; P<0.01], African American race (OR 0.37; P=0.03) and previous treatment response (OR 0.46; P=0.03). Rates of severe anaemia (45.5 vs. 58.6% in coinfected and monoinfected patients, respectively; P=0.18) were similar in the two groups, but rash (15.2 vs. 34.5%, respectively; P=0.03) and rectal symptoms (12.1 vs. 43.1%, respectively; P<0.01) were less common in coinfected patients. ConclusionsVirological responses of coinfected and monoinfected patients did not differ significantly, but tended to be higher in coinfected patients, who had a 60.6% SVR12 rate."
According to the news editors, the research concluded: "Telaprevir-based triple therapy is a promising option for coinfected patients with well-controlled HIV infection."
For more information on this research see: Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Medicine, 2014;15(2):108-115. HIV Medicine can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; HIV Medicine - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1468-1293)
The news editors report that additional information may be obtained by contacting V. Martel-Laferriere, Johns Hopkins University, Dept. of Med, Div Infect Dis, Baltimore, MD, United States. Additional authors for this research include S. Brinkley, K. Bichoupan, S. Posner, A. Stivala, P. Perumalswami, T.D. Schiano, M. Sulkowski, D.T. Dieterich and A.D. Branch (see also Immune System Diseases and Conditions).
Keywords for this news article include: HCV, Antiretrovirals, Drugs, Therapy, Maryland, HIV/AIDS, Virology, Baltimore, Treatment, Hepatology, RNA Viruses, Retroviridae, United States, HIV Infections, Liver Diseases, Gastroenterology, Hepatitis C Virus, Infectious Disease, Vertebrate Viruses, Primate Lentiviruses, Flaviviridae Infections, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC